Verrica (VRCA) COO buys 6,000 shares at $4.98 in open-market trade

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. (VRCA) reported that its Chief Operating Officer, David Zawitz, purchased 6,000 shares of common stock in an open-market or private transaction on 2026-08-17 at a weighted average price of $4.98 per share. Following this transaction, he directly holds 27,000 shares of Verrica common stock. The shares were bought in multiple trades at prices ranging from $4.90 to $5.00 per share.

Insider Trade Summary

Net Buyer: 6,000 shares

Net Buy 1 txn

Insider Zawitz David

Role Chief Operating Officer

Bought 6,000 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	6,000	$4.98	$30K

Holdings After Transaction: Common Stock — 27,000 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 6,000 shares Weighted average purchase price: $4.98 per share Price range of trades: $4.90 to $5.00 per share +1 more

4 metrics

Shares purchased 6,000 shares Common stock purchased by COO David Zawitz on 2026-08-17

Weighted average purchase price $4.98 per share Average price for 6,000 VRCA shares purchased on 2026-08-17

Price range of trades $4.90 to $5.00 per share Range of individual trade prices for the 6,000-share purchase

Shares owned after transaction 27,000 shares Direct VRCA common stock holdings of COO David Zawitz after the purchase

Key Terms

weighted average price, open market or private transaction, beneficial ownership

3 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Purchase in open market or private transaction"

beneficial ownership financial

"full information regarding the number of shares purchased"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transaction did Verrica Pharmaceuticals (VRCA) report for David Zawitz?

Verrica reported that COO David Zawitz purchased 6,000 shares of VRCA common stock. The transaction occurred on 2026-08-17 in an open-market or private transaction at a weighted average price of $4.98 per share.

At what price did the Verrica Pharmaceuticals (VRCA) COO buy his shares?

COO David Zawitz bought 6,000 VRCA shares at a weighted average price of $4.98 per share. According to the disclosure, the trades were executed in multiple lots with prices ranging from $4.90 to $5.00 per share.

How many Verrica Pharmaceuticals (VRCA) shares does the COO hold after this Form 4 trade?

After the reported purchase, COO David Zawitz directly owns 27,000 shares of Verrica common stock. This reflects an increase of 6,000 shares from this open-market or private transaction reported in the Form 4 filing.

Was the Verrica Pharmaceuticals (VRCA) insider trade made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating the trade was made under a trading plan. The transaction is described simply as a purchase in an open-market or private transaction.

What does the price range in the Verrica Pharmaceuticals (VRCA) Form 4 footnote mean?

The footnote explains the reported $4.98 is a weighted average price. The 6,000 shares were purchased in multiple trades at prices from $4.90 to $5.00. Detailed trade-by-trade prices are available upon request from the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 05:01 PM Accepted by SEC EDGAR 08/18/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zawitz David

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 W. GAY ST., SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P		6,000	A	$4.98(1)	27,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Jayson Rieger, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)